Our mission is to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification.
Founded in 2012 by Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing which underpins the market-leading Illumina® sequencing technology, and Dr Bobby Yerramilli-Rao, Cambridge Epigenetix is pioneering the epigenetics revolution.
- Seminal 5hmC publications released
Professor Anjana Rao’s team at Harvard Medical School and Dr Nathaniel Heintz’s group at Rockefeller University independently publish on a new epigenetic DNA modification - 5-hydroxymethylcytosine (5hmC).
- oxBS technique invented
The technique of oxBS is invented by Professor Sir Shankar Balasubramanian’s group at the University of Cambridge, allowing, for the first time, single-base resolution analysis of 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC).
- Cambridge Epigenetix founded
Cambridge Epigenetix founded to commercialise oxBS, providing access to the wider epigenetics research community.
- TrueMethyl oxBS kits launched
TrueMethyl oxBS kits launched providing reproducible and accurate analysis of 5hmC and 5mC.
- £5.5M Series A funding round
Cambridge Epigenetics raises $5.5M in Series A funding to further develop and commercialise tools for epigenetic analysis.
- $21M Series B funding round
Cambridge Epigenetics raises $21M in Series B funding to support further expansion of the business and investment in initial epigenetic biomarker discovery programmes utilising our proprietary platforms.
- New TrueMethyl Kit launched
TrueMethyl Whole Genome kit launched to further streamline epigenetics discoveries.
- High-profile SAB established
Cambridge Epigenetix establishes Scientific Advisory Board comprising experts within oncology, liquid biopsy and ageing to further drive the company’s transition towards epigenetic biomarker discovery.
- Fundamental methylation IP licensed
Cambridge Epigenetix licenses fundamental DNA methylation IP from Boston Children’s Hospital providing exclusive access to best-in-class techniques and freedom to commercialise novel epigenetic assays.
- HMCP: A disruptive new discovery platform
The company develops HMCP, a highly sensitive, high-throughput platform for high-resolution analysis of 5hmC, enabling cost-effective biomarker discovery.
- 5hmC diagnostic pilot study
Pilot studies using HMCP allow stratification of case vs control samples for a range of cancer types from liquid biopsy (LQB) samples - allowing the development of minimally invasive epigenetic-based assays for early cancer detection.
- New purpose-built facilities
Rapid growth prompts move to new purpose-built facilities allowing further expansion of biomarker discovery and validation capabilities.
- TrueMethyl licensed to NuGEN
Cambridge Epigenetix licenses TrueMethyl oxBS technology to NuGen Technologies Inc, allowing the company to fully focus on epigenetic biomarker discovery and diagnostic assay development programmes.
Dr. Jason Mellad
Chief Executive Officer
Dr. Joanne Mason
Vice President Biomarker Discovery
Dr. Vitali Proutski
Vice President of Informatics
Director of Human Resources
Professor Sir Shankar Balasubramanian FRS
Co-Founder and Chair of the SAB
Dr. Bobby Yerramilli-Rao
Timothy J Rink, MD, ScD
General Partner, GV
Managing Partner, Ahren Innovation Capital
Roelof F. Botha
Partner, Sequoia Capital
Dr. Martin Murphy
CEO, Syncona Partners LLP
Co-Founder and Managing Partner, New Science Ventures
Professor Wolf Reik
Head of the Epigenetics Programme, Babraham Institute
Professor Jay Shendure
Professor of Genome Sciences, University of Washington
Professor Anjana Rao
Head of the Division of Signalling and Gene Expression, La Jolla Institute
Professor Mark Dawson
Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre